MAPLE trial endpoint: PhenoBiome prebiotic raises gut microbial diversity, measured on Perseus Biomics’ DynaMAP platform

Clinical trial shows significant gain in gut diversity alongside improved quality-of-life scores; DynaMAP validated against sequencing for microbiome read-outs.

PALM SPRINGS, CA, UNITED STATES, September 29, 2026 /EINPresswire.com/ -- PhenoBiome today reported results from its MAPLE clinical trial, an eight-week study of a personalized nutritional (prebiotic) supplement in adults, run in collaboration with Perseus Biomics using the DynaMAP microbiome-profiling platform. The trial met its primary microbiome endpoint: species-level Shannon diversity rose by 0.55 points (from 4.91 to 5.46; p = 0.010) across the twelve completers, with eight of twelve gaining diversity against their own baseline.

The gain came from sub-dominant species rather than a reshuffling of the community’s most abundant members. The six leading genera trended to held steady (54.2% of the community at baseline, 52.9% afterward; p = 0.85), while the rise in evenness appeared further down the population. Genus-level Shannon moved in parallel (+0.41; p = 0.034). Species richness shifted in the same direction, adding 56 observed species per sample, though this did not reach significance at the trial’s size (p = 0.052).